Multidisciplinary management of metastatic renal cell carcinoma: a narrative review.
- 1Division of Urology and Urologic Oncology, Department of Surgery, City of Hope National Medical Center, Duarte, California, USA.
Abstract
Metastatic renal cell carcinoma (mRCC) has historically been associated with poor oncologic outcomes and limited therapeutic options. However, over the past two decades, the mRCC treatment landscape has evolved considerably with the introduction of targeted therapies, delivered either in isolation or in combination with local therapies. This narrative review aims to summarize current evidence for the management of mRCC, with a particular focus on the role of local therapy after systemic therapy. Relevant articles were found by querying the PubMed database using various combinations of the keywords "Metastasis", "Renal Cell Carcinoma", "Systemic Therapy", and "Immunotherapy". Original research studies, systematic reviews, and meta-analyses providing current evidence for the management of mRCC or describing the role of local therapy after systemic therapy in mRCC were included; non-English language studies were excluded. The systemic therapy landscape for mRCC is dominated by immuno-oncology (I/O)/IO combination therapy, IO/tyrosine kinase inhibitor (TKI) combination therapy, and TKI monotherapy. Local therapy before or after systemic therapy has an important role in mRCC management. Cytoreductive nephrectomy (CN), either upfront (before systemic therapy) or deferred (after systemic therapy), is widely used as a local treatment at the primary tumor site. Meanwhile, local treatment strategies implemented at the metastatic site(s), typically after systemic therapy, include metastasectomy, stereotactic radiotherapy, and thermal ablation. Given the vast modern landscape but heterogeneous response of mRCC treatment strategies, clinical decision-making in the management of this disease is increasingly being guided by risk stratification, biomarkers, multidisciplinary deliberations, and quality of life (QoL) considerations. mRCC management requires individualized care, shared decision-making, and multidisciplinary approaches that integrate oncologic outcomes with patient QoL. Ongoing clinical trials and future research should prioritize the identification of biomarkers to improve patient selection, optimize treatment strategies, and minimize morbidity and toxicity to enhance patient outcomes.
Related
- Cervical Chylous Fistula After Lymphadenectomy for Differentiated Thyroid Carcinoma: Anatomy, Risk Factors, and Management Strategies—A Narrative Review
- Avoidant/Restrictive Food Intake Disorder in Children and Adolescents: Nutritional Risk, Diagnostic Boundaries, and Multidisciplinary Care—A Narrative Review
- Multidisciplinary Single Stage Surgical Management of Advanced Breast Carcinoma With Concomitant Left Atrial Myxoma
- Pulmonary Epithelioid Trophoblastic Tumor Without Demonstrable Uterine Involvement: A Case Report and Literature Review Highlighting Diagnostic Challenges and Multidisciplinary Management
- Multidisciplinary team management and the survival of head and neck cancer patients: a systematic review and meta-analysis
BibTeX
@article{fribourgliendo2026multidisciplinary,
title = {{Multidisciplinary management of metastatic renal cell carcinoma: a narrative review.}},
author = {Rodrigo A Fribourg-Liendo and Anjaney Kothari and Wesley Yip},
journal = {Translational andrology and urology},
year = {2026},
month = oct,
doi = {10.21037/tau-2026-0710},
url = {https://europepmc.org/article/MED/42997216},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - Multidisciplinary management of metastatic renal cell carcinoma: a narrative review.
AU - Rodrigo A Fribourg-Liendo
AU - Anjaney Kothari
AU - Wesley Yip
PY - 2026
DA - 2026/10/23
JO - Translational andrology and urology
DO - 10.21037/tau-2026-0710
UR - https://europepmc.org/article/MED/42997216
AB - Metastatic renal cell carcinoma (mRCC) has historically been associated with poor oncologic outcomes and limited therapeutic options. However, over the past two decades, the mRCC treatment landscape has evolved considerably with the introduction of targeted therapies, delivered either in isolation or in combination with local therapies. This narrative review aims to summarize current evidence for the management of mRCC, with a particular focus on the role of local therapy after systemic therapy. Relevant articles were found by querying the PubMed database using various combinations of the keywords "Metastasis", "Renal Cell Carcinoma", "Systemic Therapy", and "Immunotherapy". Original research studies, systematic reviews, and meta-analyses providing current evidence for the management of mRCC or describing the role of local therapy after systemic therapy in mRCC were included; non-English language studies were excluded. The systemic therapy landscape for mRCC is dominated by immuno-oncology (I/O)/IO combination therapy, IO/tyrosine kinase inhibitor (TKI) combination therapy, and TKI monotherapy. Local therapy before or after systemic therapy has an important role in mRCC management. Cytoreductive nephrectomy (CN), either upfront (before systemic therapy) or deferred (after systemic therapy), is widely used as a local treatment at the primary tumor site. Meanwhile, local treatment strategies implemented at the metastatic site(s), typically after systemic therapy, include metastasectomy, stereotactic radiotherapy, and thermal ablation. Given the vast modern landscape but heterogeneous response of mRCC treatment strategies, clinical decision-making in the management of this disease is increasingly being guided by risk stratification, biomarkers, multidisciplinary deliberations, and quality of life (QoL) considerations. mRCC management requires individualized care, shared decision-making, and multidisciplinary approaches that integrate oncologic outcomes with patient QoL. Ongoing clinical trials and future research should prioritize the identification of biomarkers to improve patient selection, optimize treatment strategies, and minimize morbidity and toxicity to enhance patient outcomes.
SN - 2223-4691
ER -